Abstract
Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has adverse events including infusion reactions, op-portunistic infections, and the potential for the event such as reactivation of latent tuberculosis. Cutaneous adverse reactions of TNF-α agents include skin rash, urticaria, pruritus, lupus-like eruption, and injection site reactions. Most of all, psoriasis or psoriasiform dermatitis induced by infliximab treatment for Crohn's disease is rarely reported in Korea. We report a case of psoriasis induced by infliximab treatment for Crohn's disease with a review of world literature.
REFERENCES
1. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002; 97:2962–2972.
2. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease–seven years on. Aliment Pharmacol Ther. 2006; 23:451–463.
3. Fidder H, Schnitzler F, Ferrante M, et al. Longterm safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58:501–508.
4. Wollina U, Hansel G, Koch A, Schö nlebe J, Köstler E, Haroske G. Tumor necrosis factoralpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008; 9:1–14.
5. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007; 143:223–231.
6. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007; 34:468–472.
7. Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis. 2007; 80:231–237.
8. Umeno J, Matsumoto T, Jo Y, Ichikawa M, Urabe K, Iida M. Psoriasis during anti-tumor necrosis factoralpha therapy for Crohn's disease. Inflamm Bowel Dis. 2007; 13:1188–1189.
9. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol. 2005; 30:713–714.
10. Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factoralpha antagonist. Inflamm Bowel Dis. 2007; 13:1059–1061.
11. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factoralpha antagonist therapy: a case series. J Rheumatol. 2007; 34:380–385.
12. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005; 52:2513–2518.
13. Park BC, Lim HJ, Kim BS, Lee WJ, Kim DW, Lee SJ. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann Dermatol. 2009; 21:60–62.
14. Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factoralpha antagonist therapy. Korean J Dermatol. 2008; 46:721–723.
15. Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with Infliximab in Crohn's disease-the experience of single center in Korea. Korean J Gastroenterol. 2005; 46:48–55.
16. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009; 102:1133–1140.
17. Mease P. TNFalpha therapy in psoriasis arthritis and psoriasis. Ann Rheum Dis. 2004; 63:755–758.